海昇药业
(920656)
| 流通市值：11.27亿 | | | 总市值：13.81亿 |
| 流通股本：8162.86万 | | | 总股本：1.00亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 208,509,960.72 | 141,142,471.8 | 65,642,203.39 | 220,598,316.5 |
| 营业收入 | 208,509,960.72 | 141,142,471.8 | 65,642,203.39 | 220,598,316.5 |
| 二、营业总成本 | 137,132,886.25 | 90,517,235.86 | 44,276,393.9 | 149,016,474.19 |
| 营业成本 | 116,946,222.86 | 76,629,442.94 | 36,954,558.56 | 126,003,200.09 |
| 税金及附加 | 2,666,010.02 | 2,050,028.56 | 520,252.07 | 1,865,460.45 |
| 销售费用 | 2,946,046.67 | 1,879,484.55 | 1,636,967.64 | 2,635,586.54 |
| 管理费用 | 5,796,177.69 | 3,980,530.19 | 2,173,614.54 | 8,618,459.93 |
| 研发费用 | 7,641,045.71 | 5,097,662.1 | 2,747,108.04 | 10,529,197.62 |
| 财务费用 | 1,137,383.3 | 880,087.52 | 243,893.05 | -635,430.44 |
| 其中:利息收入 | 1,780,488.93 | 1,030,772.66 | 513,649.22 | 1,346,462.58 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | - | - | 216,333 |
| 加:投资收益 | 4,224,351.49 | 3,450,535.06 | 1,845,792.75 | 6,984,077.42 |
| 资产减值损失(新) | -3,085.35 | 18,487.22 | -77,115.85 | -472,839.65 |
| 信用减值损失(新) | -13,245.87 | -168,053.92 | -372,465.11 | -462,152.11 |
| 其他收益 | 861,779.78 | 684,224.56 | 456,483.46 | 2,322,669.21 |
| 四、营业利润 | 76,446,874.52 | 54,610,428.86 | 23,218,504.74 | 80,169,930.18 |
| 加:营业外收入 | 35,028 | 35,028 | - | 19,800 |
| 减:营业外支出 | 100,250 | 100,250 | - | 1,228.74 |
| 五、利润总额 | 76,381,652.52 | 54,545,206.86 | 23,218,504.74 | 80,188,501.44 |
| 减:所得税费用 | 10,470,049.94 | 7,524,099.44 | 3,126,024.78 | 10,731,517.92 |
| 六、净利润 | 65,911,602.58 | 47,021,107.42 | 20,092,479.96 | 69,456,983.52 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 65,911,602.58 | 47,021,107.42 | 20,092,479.96 | 69,456,983.52 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 65,911,602.58 | 47,021,107.42 | 20,092,479.96 | 69,456,983.52 |
| 扣除非经常损益后的净利润 | 62,391,380.01 | 44,158,628.82 | 18,523,556.12 | 62,534,517.09 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.66 | 0.47 | 0.2 | 0.69 |
| (二)稀释每股收益 | 0.66 | 0.47 | 0.2 | 0.69 |
| 九、综合收益总额 | 65,911,602.58 | 47,021,107.42 | 20,092,479.96 | 69,456,983.52 |
| 归属于母公司股东的综合收益总额 | 65,911,602.58 | 47,021,107.42 | 20,092,479.96 | 69,456,983.52 |
| 公告日期 | 2026-10-27 | 2026-08-20 | 2026-04-16 | 2026-04-16 |
| 审计意见(境内) | | | | 标准无保留意见 |